The Construction and Validation of a new Predictive Model for Overall Survival of Clear Cell Renal Cell Carcinoma Patients with Bone Metastasis Based on Machine Learning Algorithm

被引:3
|
作者
Le, Yijun [1 ]
Xu, Wen [2 ]
Guo, Wei [1 ,3 ]
机构
[1] Peking Univ Peoples Hosp, Musculoskeletal Tumor Ctr, Beijing, Peoples R China
[2] Peking Univ, Dept Dermatol, Peoples Hosp, Beijing, Peoples R China
[3] Peking Univ, Musculoskeletal Tumor Ctr, Peoples Hosp, 11 Xizhimen South St, Beijing 100044, Peoples R China
关键词
clear cell renal cell carcinoma; bone metastasis; SEER; overall survival; machine learning; PROGNOSTIC-FACTORS; CANCER; DIAGNOSIS; IMPACT; YOUNG;
D O I
10.1177/15330338231165131
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundThis study aimed to develop and validate predictive models based on machine learning (ML) algorithms for patients with bone metastases (BM) from clear cell renal cell carcinoma (ccRCC) and to identify appropriate models for clinical decision-making. MethodsIn this retrospective study, we obtained information on ccRCC patients diagnosed with bone metastasis (ccRCC-BM), from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 (n = 1490), and collected clinicopathological information on ccRCC-BM patients at our hospital (n = 42). We then applied four ML algorithms: extreme gradient boosting (XGB), logistic regression (LR), random forest (RF), and Naive Bayes model (NB), to develop models for predicting the overall survival (OS) of patients with bone metastasis from ccRCC. In the SEER dataset, 70% of the patients were randomly divided into training cohorts and the remaining 30% were used as validation cohorts. Data from our center were used as an external validation cohort. Finally, we evaluated the model performance using receiver operating characteristic curves (ROC), area under the ROC curve (AUC), accuracy, specificity, and F1-scores. ResultsThe mean survival times of patients in the SEER and Chinese cohort were 21.8 months and 37.0 months, respectively. Age, marital status, grade, T stage, N stage, tumor size, brain metastasis, liver metastasis, lung metastasis, and surgery were included in the ML model. We observed that all four ML algorithms performed well in predicting the 1-year and 3-year OS of patients with ccRCC-BM. ConclusionML is useful in predicting the survival of patients with ccRCC-BM, and ML models can play a positive role in clinical applications.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma
    Shinmei, Shunsuke
    Sakamoto, Naoya
    Goto, Keisuke
    Sentani, Kazuhiro
    Anami, Katsuhiro
    Hayashi, Tetsutaro
    Teishima, Jun
    Matsubara, Akio
    Oue, Naohide
    Kitadai, Yasuhiko
    Yasui, Wataru
    INTERNATIONAL JOURNAL OF UROLOGY, 2013, 20 (05) : 468 - 477
  • [22] METASTATIC TUMOR DIAMETER RESPONSE IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA IS ASSOCIATED WITH OVERALL SURVIVAL
    Pieretti, Alberto
    Shapiro, Daniel
    Westerman, Mary E.
    Hwang, Hyunsoo
    Wang, Xuemei
    Segarra, Luis A.
    Campbell, Matthew T.
    Tannir, Nizar
    Jonasch, Eric
    Wood, Christopher G.
    Karam, Jose
    JOURNAL OF UROLOGY, 2021, 206 : E676 - E676
  • [23] Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival
    Pieretti, Alberto C.
    Shapiro, Daniel D.
    Westerman, Mary E.
    Hwang, Hyunsoo
    Wang, Xuemei
    Segarra, Luis A.
    Campbell, Matthew T.
    Tannir, Nizar M.
    Jonasch, Eric
    Matin, Surena F.
    Wood, Christopher G.
    Karam, Jose A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (12) : 837.e9 - 837.e17
  • [24] Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients
    Kroeze, Stephanie G. C.
    Vermaat, Joost S.
    van Brussel, Aram
    van Melick, Harm H. E.
    Voest, Emile E.
    Jonges, Trudy G. N.
    van Diest, Paul J.
    Hinrichs, John
    Bosch, J. L. H. Ruud
    Jans, Judith J. M.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (18) : 3375 - 3382
  • [25] Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma
    Tian, X.
    Shuxuan, Z.
    Qu, Y.
    Hailiang, Z.
    Dingwei, Y.
    EUROPEAN UROLOGY, 2024, 85 : S1055 - S1055
  • [26] Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma
    Xi Tian
    Shuxuan Zhu
    Wangrui Liu
    Xinrui Wu
    Gaomeng Wei
    Ji Zhang
    Aihetaimujiang Anwaier
    Cong chen
    Shiqi Ye
    Xiangxian Che
    Wenhao Xu
    Yuanyuan Qu
    Hailiang Zhang
    Dingwei Ye
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 17451 - 17466
  • [27] Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma
    Tian, Xi
    Zhu, Shuxuan
    Liu, Wangrui
    Wu, Xinrui
    Wei, Gaomeng
    Zhang, Ji
    Anwaier, Aihetaimujiang
    Chen, Cong
    Ye, Shiqi
    Che, Xiangxian
    Xu, Wenhao
    Qu, Yuanyuan
    Zhang, Hailiang
    Ye, Dingwei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (19) : 17451 - 17466
  • [28] Construction and Validation of an Autophagy-Related Prognostic Risk Signature for Survival Predicting in Clear Cell Renal Cell Carcinoma Patients
    Yang, Huiying
    Han, Mengjiao
    Li, Hua
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [29] A novel prognostic model based on six methylation-driven genes predicts overall survival for patients with clear cell renal cell carcinoma
    Zhou, Hongmin
    Xie, Tiancheng
    Gao, Yuchen
    Zhan, Xiangcheng
    Dong, Yunze
    Liu, Ding
    Xu, Yunfei
    FRONTIERS IN GENETICS, 2022, 13
  • [30] Bone Marrow Metastasis in Clear Cell Renal Cell Carcinoma: A Case Study
    Khan, Samreen
    Awan, Sara A.
    Jahangir, Sehreen
    Kamran, Shawana
    Ahmad, Imran N.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (03)